Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet
The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.
The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.
WSJ News ExclusiveMarketsInsider sales at bank are exempt from normal disclosure rules
MarketsStocksHere are seven major companies whose stocks moved on the week’s news
MarketsFinancial RegulationThe stock tumbled after the CEO’s sale and fell further when electric-vehicle maker said it had delivered fewer cars ...
The industry that made its name taking private big corporations has shifted its focus to smaller targets, some of which ...